SE Report or PMTA? Choosing a Tobacco Pathway

Launching a new tobacco product in the U.S. requires FDA premarket authorization. For many manufacturers, the key question is whether the product can use the Substantial Equivalence (SE) pathway or needs a Premarket Tobacco Product Application (PMTA).

The right pathway depends largely on the product’s relationship to an eligible predicate and the scientific evidence needed to support marketing.

What Is the SE Pathway?

The SE pathway allows a manufacturer to compare a new tobacco product with a legally marketed predicate product.

FDA may find a product substantially equivalent when:

• It has the same characteristics as the predicate; or
• Its differences do not raise different questions of public health.

An eligible predicate generally must have been commercially marketed in the U.S. as of February 15, 2007, or have previously received an FDA substantial equivalence order. The comparison must be to a single eligible predicate—not a combination of multiple products.

An SE Report typically includes product descriptions, ingredient and material information, design comparisons, manufacturing information, stability data, comparative testing, health information, and environmental information.

When Does PMTA Make More Sense?

PMTA is the broader pathway. A manufacturer can submit a PMTA for any new tobacco product, including products that do not qualify for SE.

Instead of primarily demonstrating substantial equivalence to a predicate, the applicant must provide scientific evidence supporting FDA’s determination that marketing the product would be appropriate for the protection of public health (APPH).

FDA considers factors including:

• Risks and benefits to the population as a whole
• Whether existing tobacco users are more or less likely to stop using tobacco
• Whether non-users are more or less likely to begin using tobacco
• Manufacturing methods, facilities, and controls

PMTAs therefore generally require a broader evidence package covering the product, manufacturing, toxicology, behavioral and clinical considerations, and other information required by FDA regulations.

SE vs. PMTA: The Practical Difference

The most important question is not simply which pathway appears easier. It is whether the product, predicate, and evidence actually support the pathway.

Common SE Problems

SE submissions can become difficult when the predicate is poorly selected or the differences between products are not adequately evaluated.

Common issues include:

• Predicate is not eligible
• Comparison uses multiple predicates
• Product differences are not clearly identified
• Comparative testing is incomplete
• Test methods or acceptance criteria are inadequate
• Differences create questions of public health that the submission does not address
• Product descriptions are inconsistent across the application

FDA specifically highlights product characteristics, comparative testing, predicate eligibility, and complete submission information as important parts of an SE Report.

Common PMTA Challenges

PMTA preparation has a different challenge: building a complete scientific story around the product.

Manufacturers should be prepared to address:

• Product chemistry and toxicology
• Manufacturing controls
• Product consistency and specifications
• Nonclinical and clinical evidence where applicable
• Abuse liability and dependence considerations
• Consumer behavior
• Initiation and cessation
• Marketing plans and population impact
• Environmental requirements
• Postmarket requirements

FDA’s PMTA review can include acceptance, filing, scientific review, deficiency requests, and ultimately a marketing granted order or marketing denial order.

How to Choose the Right Pathway

Before preparing the submission, manufacturers should conduct a pathway assessment.

1. Identify the exact product.
Define the product’s ingredients, materials, design, nicotine content, delivery characteristics, manufacturing process, and intended use.

2. Evaluate potential predicates.
For an SE strategy, confirm that the proposed predicate is legally eligible and that the comparison is scientifically defensible.

3. Map the differences.
Do not simply list similarities. Identify every meaningful difference and determine whether it could raise a different question of public health.

4. Assess the evidence burden.
If the SE comparison cannot adequately support the product, forcing the product into an SE strategy can create regulatory risk.

5. Build the pathway around FDA’s standard.
The objective is not to choose the pathway with the shortest-looking submission. It is to choose the pathway that the product and available evidence can actually support.

FDA Submission Process Is Also Changing

FDA currently encourages manufacturers to use CTP Portal NextGen for PMTA and SE submissions. FDA has stated that by November 14, 2026, applicants should use the web-based forms for PMTA and SE submissions; eSubmitter will no longer be available for those submissions after that date, although PDF submission options remain available for applicants unable to submit online.

Bottom Line

SE is primarily a predicate-comparison pathway. PMTA is an APPH pathway.

If a product has a strong, eligible predicate and its differences can be adequately supported, SE may be the appropriate route. If there is no suitable predicate—or the product’s characteristics and evidence require a broader public-health assessment—PMTA may be the better strategy.

Choosing the pathway before developing the evidence package can prevent significant rework and reduce the risk of an avoidable FDA refusal or negative decision.

Need help determining whether your tobacco product is better suited for SE or PMTA? JJCC Group can help assess the product, predicate strategy, evidence requirements, and submission pathway before you invest in the full application.